1 week Ago By ABMN Staff
Lifecore Biomedical ( NASDAQ:LFCR – Get Free Report ) announced its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
27) by $0.02, Zacks reports. Lifecore Biomedical had a net margin of 5.
09% and a negative return on equity of 382.65%. Lifecore Biomedical Price Performance LFCR stock opened at $6.
66 on Friday. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.
80 and a current ratio of 1.83. The firm has a market cap of $245.
27 million, a P/E ratio of 83.25 and a beta of 0.99.
The firm’s fifty day moving average is $6.98 and its 200 day moving average is $5.77.
Lifecore Biomedical has a 52 week low of $3.68 and a 52 week high of $8.90.
Analyst Upgrades and Downgrades Separately, Craig Hallum raised their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd.
Lifecore Biomedical Company Profile ( Get Free Report ) Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. Featured Stories Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.
com's FREE daily email newsletter ..
